Scott Hirsch - 31 Jul 2025 Form 3 Insider Report for Mallinckrodt plc

Role: Director
Signature: /s/ Mark Tyndall, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 31 Jul 2025
Net transactions value: $0
Form type: 3
Filing time: 04 Aug 2025, 20:44:25 UTC
Next filing: 18 Aug 2025
SEC: View on sec.gov

Key filing fact

Scott Hirsch filed Form 3 for Mallinckrodt plc on 04 Aug 2025.

Key facts

This page summarizes Scott Hirsch's Form 3 filing for Mallinckrodt plc.
0 reported transactions and 0 derivative rows are listed below.
Filing timestamp: 04 Aug 2025, 20:44.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC Source

Ownership activity is grounded in SEC Form 3 disclosures.

See Original Filing

Reporting Owners (1)

CIK 0002024619 Primary reporting owner

Hirsch Scott

Relationship: Director
Address: 675 MCDONNELL BLVD., HAZELWOOD
Signature: /s/ Mark Tyndall, Attorney-in-Fact
Signature date: 04 Aug 2025

Transactions Table

No ticker holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 455
Date: 31 Jul 2025
Ownership: Direct
Footnotes: F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. At the Merger Effective Time (as defined in the Transaction Agreement), each share of Endo common stock held by the reporting person immediately prior to the Merger Effective Time automatically converted into the right to receive approximately $1.31 in cash and 0.2575 ordinary shares of the Issuer without interest and subject to applicable withholding. The securities reported herein were acquired by the reporting person prior to the reporting person becoming a director of the Issuer.
F2	The reporting person became a director of the Issuer immediately following the effective time of the Business Combination.

Content

On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. At the Merger Effective Time (as defined in the Transaction Agreement), each share of Endo common stock held by the reporting person immediately prior to the Merger Effective Time automatically converted into the right to receive approximately $1.31 in cash and 0.2575 ordinary shares of the Issuer without interest and subject to applicable withholding. The securities reported herein were acquired by the reporting person prior to the reporting person becoming a director of the Issuer.

The reporting person became a director of the Issuer immediately following the effective time of the Business Combination.

Remarks:

Exhibit 24 - Power of Attorney. This Form 3 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.